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Background 
According to the World Health Organization (WHO), tuberculosis (TB) is the most important cause 
of mortality from infectious diseases with 1.4 million deaths and 10.4 million cases of disease in 
2015 (1). Furthermore, the high global TB burden was compounded by an estimated 480,000 new 
cases of multidrug-resistant TB (MDR-TB) and 100,000 patients with rifampicin-resistant TB (RR-
TB), which are more difficult to treat, in 2015 (1). In the WHO European Region, 36,970 deaths 
were reported, in association with over 320,000 TB incident cases (1,2).  
Worldwide, the annual decline of the TB incidence rate from 2014 to 2015 was only 1.5%. 
However, to achieve the first milestones of the End TB Strategy this indicator should increase at 5% 
by 2020 and then accelerate further (2).  
Although TB disproportionately affects vulnerable population groups (i.e., individuals at higher risk 
of exposure to discrimination, hostility, or economic adversity, such as migrants and refugees, 
immune suppressed individuals either for HIV infection or biological therapy), the Mycobacterium 
tuberculosis transmission does not respect any borders and can virtually involve anybody living in 
high-, middle- and low-income countries. The occurrence of the disease generates unacceptable 
human suffering and catastrophic costs to patients and their families, as well as to the society as a 
whole (3-6). 
Thus, sustainable and effective efforts are needed to ensure quality prevention, diagnosis, and 
treatment for TB and Latent TB Infection (LTBI) (5,6). 
Those should be immediately implemented as integral part of both the human rights of the affected 
individuals and the public health pre-requisites to control and eliminate TB, while preventing 
further development of multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB 
(XDR-TB) (7,8). 
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On the occasion of the  World TB Day 2017 and as a strong message contributing to the Ministerial 
Conference ‘A multisectoral response to End TB in the sustainable development era’, to be held in 
Moscow on 16-17 November 2017, the European Respiratory Society (ERS) and the UNION 
(International Union against Tuberculosis and Lung Disease) Europe Region would like to highlight 
the following statements: 
1. TB is neither highly virulent nor easily transmitted, and is treatable. Therefore, efforts 
should be implemented to rapidly detect and treat it (both drug-susceptible and M/XDR-TB cases). 
Provision of adequate treatment is, in fact, essential to break the chain of transmission within the 
community, while protecting uninfected individuals by the extent possible (5, 6, 8); 
2. Diagnosis of LTBI, TB, and M/XDR-TB is not always easy to perform in all settings and 
circumstances, particularly in centres hosting large numbers of at high-risk individuals including 
migrants and refugees (4,9-15); therefore, national political commitment is immediately required to 
address this important gap in the cascade of care; 
3. Sub-optimal or inappropriate medical management of LTBI, TB, and M/XDR-TB and/or 
inadequate follow-up of individuals or patients will hinder TB control and elimination efforts 
(5,6,9); therefore, education of healthcare workers and identification of reference centres should be 
a priority to improve the public health outcomes and reduce the waste of healthcare-related financial 
resources. 
Recommendations  
Health authorities, national TB programmes, national and international technical agencies, civil 
society organisations and donor agencies are urged to prioritise TB, prevention, care  and control, 
particularly among the most vulnerable populations and are strongly recommended to: 
TB prevention 
- Implement the necessary infection control measures (managerial activities, administrative 
and environmental controls, personal protection) (9-11); 
- Implement the principles of the WHO LTBI guidelines in terms of both diagnosis and 
treatment (6);  
- Implement the LTBI monitoring and evaluation activities recently proposed by WHO (6,16); 
- Advocate for more effective medicines for LTBI management including the registration of 
rifapentine in Europe to allow the prescription of shorter and effective regimens to treat 
LTBI (6);  
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- Promote research on new, effective vaccines and diagnostics and shorter and more effective 
treatment regimens (1); 
TB diagnosis 
- Scale-up rapid diagnosis of TB and drug resistance forms using the diagnostic WHO 
endorsed molecular methods  and referral of the patient to treatment  services (1,5,9,17); 
TB treatment 
- Ensure people-centred, age-sensitive, gender-specific services supporting adherence and 
universal access to TB services (1,5,9,17); 
- Ensure adequate treatment of drug-susceptible cases, to achieve the highest success rate; 
- Implement quality-based management of drug-resistant and MDR-TB cases;; 
- Promote the use of therapeutic drug monitoring (TDM) to prevent, detect and manage of 
adverse events (18,19); 
- Promote continuous medical education on TB for all healthcare workers potentially in 
charge of TB cases. 
- -Consider psychosocial support and relevant measures to enable and support the patients and 
their families complete their treatment. 
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